Colorectal cancer is a carcinoma arising from the luminal surface of the colon.
It is the 2nd most common cancer in women and third most common cancer in male worldwide. It commonly arises from adenomatous polyps.
It is strongly linked to age with 83% occurring in people ≥60 years old.
Rectal cancer is defined as cancerous lesions located within 12 cm of the anal verge.
About one-third of patients with peritoneal metastasis experience recurrence within 12 months of undergoing cytoreductive surgery (CRS) and treatment with hyperthermic intraperitoneal chemotherapy (HIPEC), with cancer type and receipt of adjuvant treatment potentially affecting the risk of early recurrence, according to a study from Singapore.
Upfront tumour sequencing with a single next-generation sequencing (NGS) test demonstrated improved sensitivity and comparable specificity with the currently used universal screening multitest approach for Lynch syndrome in patients with colorectal cancer, which highlights its role as a potential replacement for universal screening, a recent study found.
A weekly dose escalation of regorafenib was superior to starting with the standard dose of 160 mg/day for patients with refractory metastatic colorectal cancer (mCRC), according to the ReDOS* trial presented at the ASCO GI Cancers Symposium 2018.
The combination of nivolumab and ipilimumab demonstrated strong response, progression-free survival (PFS), and overall survival (OS) rates in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic or recurrent colorectal cancer (CRC), results from the phase II CheckMate-142* trial show.
Despite guidelines advocating mismatch repair (MMR) deficiency testing in individuals with colorectal cancer (CRC), particularly in young adults, uptake of MMR testing remains low, according to a large study from the US.
Indication and demand for genetic testing have increased in recent years, with tests becoming more readily available and affordable, says a leading oncologist at ESMO Asia 2017, highlighting that appreciation of ethical, social, and legal implications of testing and proper test interpretation are important for optimal patient management.
A modified dose of XELIRI with or without bevacizumab may be an alternative second-line chemotherapy treatment for patients with metastatic colorectal cancer (CRC), according to results of the noninferiority phase III AXEPT* trial.
A rare copy number variant region (CNVR) at chromosome 14q11, encompassing the CHD8 gene for chromatin modification, is associated with sporadic colorectal cancer (CRC) risk such that the loss of copy number affects the expression of genes involved in CRC tumourigenesis, a recent Singapore study has shown.
Sodium phosphate (NaP) tablets for bowel preparation prior to colonoscopy are safe, better tolerated by patients, and provide equivalent and possibly superior colon cleansing compared with standard polyethylene glycol (PEG) solution, a Korean study has found.
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
Sodium–glucose cotransporter-2 (SGLT-2) inhibitors increase the risk for diabetic ketoacidosis (DKA) by almost threefold, with molecule-specific analyses suggesting a class effect, according to a study.
In the first year following percutaneous coronary intervention for acute coronary syndrome, ticagrelor and prasugrel cuts the risk of gastrointestinal (GI) bleeding by more than 30 percent compared with clopidogrel, as shown in a large real-world study.